Youngwook Won

Biomedical Engineering
Associate Professor

Discovery Park

Youngwook Won
Areas of Expertise:
  • Bioengineering and Health
About

Faculty Info |

Education
  • 1997.03 - 2005.02 B.S. Hanyang University, College of Science & Technology (Biochemistry and Molecular Biology), Korea
  • 2006.03 - 2008.02 M.S. Hanyang University (Department of Bioengineering), Korea
  • 2008.02 - 2011.08 Ph.D. Hanyang University (Department of Bioengineering), Korea
  • 2011.09 - 2014.06 Postdoctoral Fellow University of Utah (Center for Controlled Chemical Delivery), USA
Publications
PEER-REVIEWED JOURNAL ARTICLES
  1. Cha BH, Jung M, Kim AS, Lepak VC, Colson BA, Bull DA, Won YW. AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo, Journal of Biological Engineering. (2021) 15:24
  2. Han S, Jung M, Kim AS, Lee DY, Cha BH, Putnam CW, Lim KS, Bull DA, Won YW. Peptide Adjuvant to Invigorate Cytolytic Activity of NK cells in an Obese Mouse Cancer Model, Pharmaceutics. (2021) 13(8), 1279
  3. Lim KS, Lee DY, Han S, Bull DA, Won YW. Targeted delivery of heat shock protein 90 inhibitors prevents growth of HER2-positive tumor. Biomaterials. Volume 273, June 2021, 120817
  4. Gilman KA, Han S, Won YW, Putnam CW. Complex interactions of lovastatin with 10 chemotherapeutic drugs: a rigorous evaluation of synergism and antagonism. BMC Cancer. (2021) 21:356
  5. Liu Z, Barber C, Gupta A, Wan L, Won YW, Furenlid LR, Chen Q, Desai AA, Zhao M, Bull DA, Unger EC, Martin DR. Imaging assessment of Cardioprotection mediated by a Dodecafluoropentane oxygencarrier administered during myocardial infarction. Nuclear Medicine and Biology (IF: 2.203). 2019; In Press. doi: 10.1016/j.nucmedbio.2019.01.004
  6. Lee DY, Cha BH, Jung M, Kim AS, Bull DA, Won YW*. Cell Surface Engineering and Applications in Cardiac Regeneration. Journal of Biological Engineering (IF: 5.256). 2018; 12: 28. doi: 10.1186/s13036-018-0123-6
  7. Lee DY, Kim KS, Valencia GM, Jung M, Bull DA, Won YW*. One-step Method for Instant Generation of Advanced Allogeneic NK Cells. Advanced Sciences (IF: 12.441). doi: 10.1002/advs.201800447
  8. Lim KS, Lee DY, Valencia GM, Won YW*, Bull DA* (2017). Cell surface-engineering to embed targeting ligands or tracking agents on the cell membrane. Biochem Biophys Res Commun (IF: 2.559).482(4), 1042-1047.
  9. Lim KS, Lee DY, Valencia GM, Bull DA*, Won YW* (2017). Direct Incorporation of Functional Peptides into M-DNA through Ligand-to-Metal Charge Transfer. ACS macro letters (IF: 6.131). (6), 98-102.
  10. Won YW, Ankoné M, Engbersen JF, Feijen J, Kim SW (2016). Poly(Amido Amine)s Containing Agmatine and Butanol Side Chains as Efficient Gene Carriers. Macromol Biosci (IF: 3.392). 16(4), 619-626.
  11. Lim KS, Lee DY, Valencia GM, Won YW*, Bull DA* (2015). Nano-Self-Assembly of Nucleic Acids Capable of Transfection without a Gene Carrier. Adv Funct Mater (IF: 13.325), 25(34), 5445-5451.
  12. Won YW1, Adhikary PP1, Lim KS, Kim HJ, Kim JK, Kim YH (2014). Oligopeptide complex for targeted non-viral gene delivery to adipocytes. Nat Mater (IF: 39.235), 12, 1157-64. 1Co-first author
  13. Won YW, Patel AN, Bull DA (2014). Cell surface engineering to enhance mesenchymal stem cell migration toward an SDF-1 gradient. Biomaterials (IF: 8.557), 35(21), 5627–5635.
  14. Won YW, Bull DA, Kim SW (2014). Functional polymers of gene delivery for treatment of myocardial infarct. J Control Release (IF: 7.705), 195, 110-119.
  15. Won YW, McGinn AN, Lee M, Nam K, Bull DA, Kim SW (2013). Synergistically combined gene delivery for enhanced VEGF secretion and antiapoptosis. Mol Pharm (IF: 4.787), 10(10), 3676–3683.
  16. Won YW, McGinn AN, Lee M, Nam K, Bull DA, Kim SW (2013). Post-translational regulation of a hypoxia-responsive VEGF plasmid for the treatment of myocardial ischemia. Biomaterials (IF: 8.312), 34(26), 6229-38.
  17. Lim KS, Lim MH, Won YW, Kim JK, Kang YC, Park EJ, Chae JW, Kim SM, Ryu SE, Kim Pak Y, Kim YH (2013). Dual-mode enhancement of metallothionein protein with cell transduction and retention peptide fusion. J Control Release (IF: 7.261), 171(2), 193-200.
  18. Won YW, Lee M, Kim HA, Bull DA, Kim SW (2013). Hypoxia-inducible plasmid expressing both miSHP-1 and HO-1 for the treatment of ischemic disease. J Control Release (IF: 7.261), 165(1), 22-8.
  19. Won YW, McGinn AN, Lee M, Bull DA, Kim SW (2013). Targeted gene delivery to ischemic myocardium by homing peptide-guided polymeric carrier. Mol Pharm (IF: 4.787), 10(1), 378-85.
  20. Won YW, Lee M, Kim HA, Bull DA, Kim SW (2012). Post-translational regulated and hypoxiaresponsible VEGF plasmid for efficient secretion. J Control Release (IF: 7.633), 160(3), 525-31.
  21. Kim JK1, Won YW1, Lim KS, Kim YH (2012). Low-molecular-weight methylcellulose-based thermoreversible gel/pluronic micelle combination system for local and sustained docetaxel delivery. Pharm Res (IF: 4.742), 29(2), 525-34. 1Co-first author
  22. Won YW1, Yoon SM1, Lim KS, Kim YH (2012). Self-assembled nanoparticles with dual effects of passive tumor targeting and cancer-selective anticancer effects. Adv Funct Mater (IF: 13.325), 22(6), 1199-1208.1Co-first author
  23. Won YW, Lim KS, Kim YH (2011). Intracellular organelle-targeted non-viral gene delivery systems. J Control Release (IF: 6.499), 152(1), 99-109.
  24. Won YW, Kim KM, An SS, Lee M, Ha Y, Kim YH (2011). Suicide gene therapy using reducible poly (oligo-D-arginine) for the treatment of spinal cord tumors. Biomaterials (IF: 7.404), 32(36), 9766-75.
  25. Won YW, Yoon SM, Sonn CH, Lee KM, Kim YH (2011). Nano self-assembly of recombinant human gelatin conjugated with alpha-tocopheryl succinate for Hsp90 inhibitor, 17-AAG, delivery. ACS Nano (IF: 13.709), 5(5), 3839-48.
  26. Won YW, Yoon SM, Lee KM, Kim YH (2011). Poly(oligo-D-arginine) with internal disulfide linkages as a cytoplasm-sensitive carrier for siRNA delivery. Mol Ther (IF: 6.873), 19(2), 372-80.
  27. Lim KS, Won YW, Park YS, Kim YH (2010). Preparation and functional analysis of recombinant protein transduction domain-metallothionein fusion proteins. Biochimie (IF: 3.787), 92(8), 964-70.
  28. Won YW, Kim JK, Cha MJ, Hwang KC, Choi D, Kim YH (2010). Prolongation and enhancement of the anti-apoptotic effects of PTD-Hsp27 fusion proteins using an injectable thermo-reversible gel in a rat myocardial infarction model. J Control Release (IF: 7.164), 144(2), 181-9.
  29. Won YW, Kim HA, Lee M, Kim YH (2010). Reducible poly(oligo-D-arginine) for enhanced gene expression in mouse lung by intratracheal injection. Mol Ther (IF: 7.149), 18(4), 734-42.
  30. Hyun H, Won YW, Kim KM, Lee J, Lee M, Kim YH (2010). Therapeutic effects of a reducible poly (oligo-D-arginine) carrier with the heme oxygenase-1 gene in the treatment of hypoxia-ischemic brain injury. Biomaterials (IF: 7.883), 31(34), 9128-34.
  31. Won YW, Kim YH (2009). Preparation and cytotoxicity comparison of Type A gelatin nanoparticles with recombinant human gelatin nanoparticles. Macromol Res (IF: 2.369), 17, 464-468.
  32. Won YW, Kim YH (2008). Recombinant human gelatin nanoparticles as a protein drug carrier. J Control Release (IF: 5.690), 127(2), 154-61.
NON PEER-REVIEWED JOURNAL ARTICLES
  1. Jin KM, Won YW, Kim YH (2007). Genetic recombinant protein expression system. Journal of the Research Institute of Industrial Sciences, 55, 107-115.
  2. Won YW, Jang YL, Kim JS, Jung JH, Kim YH (2010). Non-viral siRNA delivery systems. Journal of Pharmaceutical Investigation, 40, 119-129.
Patents
  1. Kim YH, Won YW (2008). Recombinant gelatin nanoparticle. (Korea patent). U.S. Patent No. 10-0819184. Washington, D.C.:U.S. Patent and Trademark Office.
  2. Kim YH, Won YW (2011). Intracellular reducible poly(oligo-arginine) for nucleic acid delivery. (Korea patent). U.S. Patent No. 10-2011-1035364. Washington, D.C.:U.S. Patent and Trademark Office.
  3. Kim YH, Won YW, Yoon SM (Registered 2013). Sun-Mi Yoon, Recombinant human gelatin-lipoic acid conjugation and use thereof. U.S. Patent No. 10-2011-0001810. Washington, D.C.:U.S. Patent and Trademark Office.
  4. Won YW, Bull DA, Lim KS (2015). BI-FUNCTIONAL ALLOSTERIC PROTEIN-DRUG MOLECULES FOR TARGETED THERAPY. U.S. Patent No. PCT/US2015/065308. Washington, D.C.:U.S. Patent and Trademark Office.
  5. Won YW, Bull DA, Patel AN (2014). COMPOSITIONS AND METHODS FOR MODIFYING THE SURFACE OF CELLS AND METHODS OF USE. U.S. Patent No. PCT/US2015/012081. Washington, D.C.:U.S. Patent and Trademark Office. Issued on 05/07/2019. Licensed to CoreA Therapeutics
  6. Won YW, Bull DA, Lee DY, Lim KS (2017). Methods and Compositions for Protein Based CAR Polypeptides. Provisional application No.:62/554,773. Licensed to Hauul Bio
  7. Won YW, Bull DA, Lee DY (2018). TARGETING MOIETY-DRUG GRAFTED IMMUNE CELL COMPOSITIONS AND METHODS OF USE. Provisional application No.: 62/733,929, PCT filed in Sep. 2019. Licensed to CoreA Therapeutics
  8. Kim YH, Lim KS, Won YW, Kim JK (2017). Adipocyte-targeting non-viral gene delivery system. Application Granted US9765329B2 (Anticipated Expiration: 2034.03.31)
  9. Won YW, Jung M, Kim AS, Bull DA (2019). Anti-Obesity Peptides and Uses Thereof. Provisional Application Filed on 04/06/2019. Licensed to Lean Life Sciences
  10. Won YW, Cha BH, Bull DA (2020). HYBRID ALLOSTERIC RECEPTOR-ENGINEERED STEM CELLS. Provisional Application Filed on 09/01/2020
  11. Won YW, Han S, Bull DA (2020). Antibody-Exatecan Conjugates for targeted cancer therapy. Provisional Application under Preparation
  12. Won YW, Han S, Bull DA (2020). Composition of a Recombinant Fusion Protein to Restore Anti-Cancer Activity of Immune Cells, Provisional Application (#63/149,417) filed on 02/15/2021
  13. Won YW, Han S, Jung DM (2021). Immune Adjuvant Peptides and Uses Thereof, Provisional Application (#63/231,368) filed on 08/10/2021
  14. Won YW, Jung DM (2021). Cosmetic Peptides for Improving Skin Rejuvenation. PCT (PCT/US2021/045045) filed on August 10, 2021
  15. Won YW, Jung DM (2021). Immune Enhancing Peptides and Uses Thereof, Provisional Application (#63/231,355) filed on 08/10/2021